iNovacia Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 11

Employees

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 1

iNovacia General Information

Description

Provider of pre-clinical research services. The company is engaged in providing drug discovery services to the pharmaceutical companies for the discovery of new medicines.

Contact Information

Website
www.inovacia.se
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Lindhagensgatan 133
  • 112 51 Stockholm
  • Sweden
Primary Industry
Drug Discovery
Acquirer
Kancera
Corporate Office
  • Lindhagensgatan 133
  • 112 51 Stockholm
  • Sweden

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

iNovacia Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore iNovacia‘s full profile, request access.

Request a free trial

iNovacia Patents

  • 12

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • Pending

  • Expiring in next 12 mo

iNovacia Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20080255153-A1 Pyrazolo[1,5- a ]-pyrimidine derivatives as human stearoyl-coa desaturase; cardiovascular, nervous system, autoimmune, metabolic and skin disorders; obesity, non-insulin-dependent diabetes; eczema, rosacea, acne, psoriasis; anticarcinogenic agents; modulation of plasma lipids Inactive 31-Aug-2007
EP-2137187-A1 Pyrazolo [1,5-a]pyrimidines as inhibitors of stearoyl-coa desaturase Inactive 28-Mar-2007
CA-2682016-A1 Pyrazolo [1,5-a]pyrimidines as inhibitors of stearoyl-coa desaturase Inactive 28-Mar-2007
JP-2010522716-A Pyrazolo [1,5-a] pyrimidines as inhibitors of stearoyl-coa desaturase Inactive 28-Mar-2007
US-20080103141-A1 Tert-butyl 4-[({5-[4-(hydroxymethyl)phenyl]pyrimidin-2-yl}oxy)methyl]piperidine-1-carboxylate; agonists of the g-protein-coupled receptor gpr119; antidiabetic, antiinflammatory agent, neuropathy, obesity; use with a dipeptidyl peptidase iv (dpp iv) inhibitor Inactive 21-Nov-2006 A61K31/4545
To view iNovacia’s complete patent history, request access »

iNovacia Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

iNovacia FAQs

  • When was iNovacia founded?

    iNovacia was founded in 2006.

  • Where is iNovacia headquartered?

    iNovacia is headquartered in Stockholm, Sweden.

  • What is the size of iNovacia?

    iNovacia has 11 total employees.

  • What industry is iNovacia in?

    iNovacia’s primary industry is Drug Discovery.

  • Is iNovacia a private or public company?

    iNovacia is a Private company.

  • What is the current valuation of iNovacia?

    The current valuation of iNovacia is .

  • What is iNovacia’s current revenue?

    The current revenue for iNovacia is .

  • When was iNovacia acquired?

    iNovacia was acquired on 17-Feb-2011.

  • Who acquired iNovacia?

    iNovacia was acquired by Kancera.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »